Sciatica - Pipeline Insight, 2020

DelveInsight’s, “Sciatica – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sciatica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Sciatica Understanding
Sciatica: Overview
Sciatica is a debilitating condition in which the patient experiences pain and/or paresthesias in the distribution of the sciatic nerve or an associated lumbosacral nerve root. Often, a common mistake is referring to any low back pain or radicular leg pain as sciatica. Sciatica is specific to the pain that is a direct result of sciatic nerve or sciatic nerve root pathology. The sciatic nerve is made up of the L4 through S2 nerve roots which coalesce at the pelvis to form the sciatic nerve. At up to 2 cm in diameter, the sciatic nerve is easily the largest nerve in the body. Sciatica pain often is worsened with flexion of the lumbar spine, twisting, bending, or coughing. The sciatic nerve provides direct motor function to the hamstrings, lower extremity adductors, and indirect motor function to the calf muscles, anterior lower leg muscles, and some intrinsic foot muscles. Also, indirectly through its terminal branches, the sciatic nerve provides sensation to the posterior and lateral lower leg as well as the plantar foot. It is an important distinction to know that most cases of sciatica result from an inflammatory condition leading to an irritation of the sciatic nerve. Conversely, direct compression of the nerve leads to more severe motor dysfunction which is often not seen, and if present, would warrant a more meticulous and expeditious workup.
Symptoms
Common Sciatica Symptoms include:
• Pain
• Weakness
• Numbness, tingling, and/or a pins-and-needles sensation
• Change in posture may aggravate or relieve pain
Diagnosis
Sciatica is a clinical diagnosis, and therefore, a thorough history and physical examination are necessary for a complete evaluation and diagnosis. Imaging is initially of little value. If warranted, plain films of the lumbosacral spine may evaluate for fracture or spondylolisthesis. Noncontrast CT scan may be performed to evaluate fracture if plain films are negative. Additionally, pain that has been persistent for 6 to 8 weeks and not responding to conservative management should be imaged. In this case, MRI is the imaging modality of choice. In cases where the neurologic deficit is the present or mass effect is suspected, immediate MRI is the standard of care in establishing the cause of the pain and ruling out pressing surgical pathology.
Treatment
It involves medical therapies such as:
• A short course of oral NSAIDs
• Opioid and nonopioid analgesics
• Muscle relaxants
• Anticonvulsants for neurogenic pain
• In the event oral NSAIDs are insufficient, a course of oral corticosteroids may be beneficial
• Localized corticosteroid injections
• Deep tissue massage may be helpful
• Surgical evaluation and correction of any structural abnormalities such as disc herniation, epidural hematoma, epidural abscess or tumor
Sciatica Emerging Drugs Chapters
This segment of the Sciatica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sciatica Emerging Drugs
• Semdexa: Scilex Pharmaceuticals
Semdexa is being developed by Scilex Pharmaceuticals for the treatment of sciatica. It is non-opioid injectable therapeutic on track to be the first and only FDA-approved epidural steroid product. It is currently in phase III stage of development.
• KLS 2031: Kolon Life Science
KLS 2031 is being developed by Kolon Life Science for the treatment of Sciatica. It blocks pain signal delivered in the brain and improves pain environment. It is currently in phase I/IIa stage of development.
• SR 419: SIMR (Australia) Biotech Pty Ltd
SR 419 is being developed by SIMR (Australia) Biotech Pty Ltd for the treatment of Unilateral Sciatica. The company is currently evaluating the efficacy, safety, tolerability, and pharmacokinetics of SR419 in participants with neuropathic pain due to Postherpetic Neuralgia, Diabetic Peripheral Neuropathy, or Unilateral Sciatica. It is currently in phase I stage of development.

Further product details are provided in the report……..
Sciatica: Therapeutic Assessment
This segment of the report provides insights about the different Sciatica drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Sciatica
There are approx. 10+ key companies which are developing the therapies for Sciatica. The companies which have their Sciatica drug candidates in the most advanced stage, i.e. phase III include Scilex Pharmaceuticals and others
• Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Sciatica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous.

• Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sciatica: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sciatica therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sciatica drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Sciatica R&D. The therapies under development are focused on novel approaches to treat/improve Sciatica.
• In March 2019, Sorrento Therapeutics stated that its majority owned subsidiary Scilex Pharmaceuticals has closed a transaction to merge with Mountain View, California, based Semnur Pharmaceuticals, Inc. (Semnur) to form a new company, Scilex Holding Company (Scilex Holding).
Sciatica Report Insights
• Sciatica Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Sciatica Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Sciatica drugs?
• How many Sciatica drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sciatica?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sciatica therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sciatica and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Breath of Life International Pharma
• Biogen
• Renovis
• Regeneron Pharmaceuticals
• SIMR (Australia) Biotech Pty Ltd
• Cephalon
• Semnur Pharmaceuticals

Key Products
• BOL-DP-o-04 + SCO
• BG00010
• REN-1654
• REGN475
• SR419
• CEP-37247
• SP-102